🏢 The company has expanded lab space in Hamburg and Durham, totaling 355,000 square feet.
🧪 This addition enhances their services, supporting complex therapeutic programs like antibody-drug conjugates and oligonucleotides.
🔍 Their GxP and GMP labs meet international health standards.
✅ LC/MS ensures innovative therapeutic support across regions.
Introduction:
BioAgilytix, a leading provider of bioanalytical testing, is expanding its capabilities through significant investments in liquid chromatography-mass spectrometry (LC/MS). This strategic development is aimed at enhancing their laboratory services and meeting the growing demand for innovative therapeutic solutions.
- BioAgilytix has announced multi-million-dollar investments in LC/MS capabilities, with expansions in their laboratories located in Hamburg, Germany, and Durham, North Carolina.
- The company now boasts a total of 355,000 square feet of laboratory space, including 24,000 square feet specifically dedicated to LC/MS services.
- Integration of LC/MS and ligand binding assay (LBA) services enables BioAgilytix to effectively handle complex projects such as antibody-drug conjugates (ADCs), peptides, and oligonucleotides.
- The newly developed facilities include Good Laboratory Practice (GxP) and Good Manufacturing Practice (GMP) compliant labs that cater to exploratory studies as well as regulated bioanalysis.
- Dave Beyerlein, the global lead for LC/MS at BioAgilytix, emphasizes the importance of consistent platforms and processes to ensure high-quality, efficient assay transfer across different sites, including international locations.
Conclusion:
The investments in LC/MS capabilities reflect BioAgilytix’s commitment to enhancing its service offerings in bioanalytical testing. By improving its laboratory infrastructure and harmonizing operational standards across its facilities, the company aims to better support the development of innovative therapies, which could positively impact pharmaceutical research and development in the future.
